N/A
Completed N=41
Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment
Breast Cancer · Breast Tumors · Cancer of Breast · Cancer of the Breast
Source: ClinicalTrials.gov NCT02891681 ↗
Enrolled (actual)
41
Serious AEs
0.0%
Results posted
Feb 2021
Primary outcomePrimary: Pathologic Response Based on Miller-Payne Grading System — 4; 1; 3; 0 Participants
Summary
To determine the accuracy of NIR/US assessment of tumor vasculature and oxygen changes in predicting and monitoring early neoadjuvant treatment response compared to pathological response.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Pathologic Response Based on Miller-Payne Grading System |
4; 1; 3; 0; 8; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Scheduled to receive neoadjuvant chemotherapy for the treatment of newly diagnosed, locally advanced breast cancer or scheduled to receive neoadjuvant endocrine therapy with the eventual goal of surgery of newly diagnosed clinical stage II-III ER+ HER2- breast cancer (for the endocrine therapy cohort)
- At least 18 years of age
- Female
- Able to understand and willing to sign an IRB-approved written informed consent document
Exclusion Criteria
- Pregnant and/or breastfeeding
- Prior history of breast cancer
- Prior history of chest wall radiation
- Prior history of breast reconstruction, reduction, or augmentation
Data sourced from ClinicalTrials.gov (NCT02891681). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.